Similar results were later obtained by adding a member of a third class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs) to two NRTIs. NNRTI-based HAART regimens have ...

Sequence variations in human immunodeficiency virus (HIV)-1 reverse ... non-subtype B isolates from untreated individuals; isolates from individuals who have received at least one nucleoside ...

Several classes of anti-HIV drugs interfere with this stage of HIV’s life cycle: nucleoside reverse transcriptase inhibitors and nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside ...

Nevirapine belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTI) of HIV. It reduces perinatal HIV transmission when administered as a 2-dose regimen, 1 dose to pregnant ...

This fixed-dose tablet combines 600mg efavirenz, 200mg emtricitabine (FTC), and 245mg tenofovir disoproxil fumarate (TDF). Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), ...

Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro. The FDA has approved ...

Juluca combines GSK’s already approved integrase inhibitor Tivicay (dolutegravir) with Janssen’s non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine), to produce a regimen that ...

The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single table ...

Azvudine is under clinical development by Henan Genuine Biotech and currently in Phase II for Colorectal Cancer.